204 related articles for article (PubMed ID: 37193898)
1. Computational drug repurposing of Akt-1 allosteric inhibitors for non-small cell lung cancer.
Baby K; Maity S; Mehta CH; Nayak UY; Shenoy GG; Pai KSR; Harikumar KB; Nayak Y
Sci Rep; 2023 May; 13(1):7947. PubMed ID: 37193898
[TBL] [Abstract][Full Text] [Related]
2.
Thongsom S; Racha S; Ei ZZ; Petsri K; Aksorn N; Chamni S; Panpuang V; Zou H; Chanvorachote P
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674871
[TBL] [Abstract][Full Text] [Related]
3. FCX-146, a potent allosteric inhibitor of Akt kinase in cancer cells: Lead optimization of the second-generation arylidene indanone scaffold.
Balasubramaniam M; Lakkaniga NR; Dera AA; Fayi MA; Abohashrh M; Ahmad I; Chandramoorthy HC; Nalini G; Rajagopalan P
Biotechnol Appl Biochem; 2021 Feb; 68(1):82-91. PubMed ID: 32067263
[TBL] [Abstract][Full Text] [Related]
4. Novel and Potential Small Molecule Scaffolds as DYRK1A Inhibitors by Integrated Molecular Docking-Based Virtual Screening and Dynamics Simulation Study.
Shahroz MM; Sharma HK; Altamimi ASA; Alamri MA; Ali A; Ali A; Alqahtani S; Altharawi A; Alabbas AB; Alossaimi MA; Riadi Y; Firoz A; Afzal O
Molecules; 2022 Feb; 27(4):. PubMed ID: 35208955
[TBL] [Abstract][Full Text] [Related]
5. Identification of potential PKC inhibitors through pharmacophore designing, 3D-QSAR and molecular dynamics simulations targeting Alzheimer's disease.
Iqbal S; Anantha Krishnan D; Gunasekaran K
J Biomol Struct Dyn; 2018 Nov; 36(15):4029-4044. PubMed ID: 29182053
[TBL] [Abstract][Full Text] [Related]
6. Microsecond molecular dynamics simulations provide insight into the ATP-competitive inhibitor-induced allosteric protection of Akt kinase phosphorylation.
Mou L; Cui T; Liu W; Zhang H; Cai Z; Lu S; Gao G
Chem Biol Drug Des; 2017 May; 89(5):723-731. PubMed ID: 27797456
[TBL] [Abstract][Full Text] [Related]
7. Repurposing of FDA-approved drugs against active site and potential allosteric drug-binding sites of COVID-19 main protease.
Yuce M; Cicek E; Inan T; Dag AB; Kurkcuoglu O; Sungur FA
Proteins; 2021 Nov; 89(11):1425-1441. PubMed ID: 34169568
[TBL] [Abstract][Full Text] [Related]
8. Pharmacophore modeling, multiple docking, and molecular dynamics studies on Wee1 kinase inhibitors.
Hu Y; Zhou L; Zhu X; Dai D; Bao Y; Qiu Y
J Biomol Struct Dyn; 2019 Jul; 37(10):2703-2715. PubMed ID: 30052133
[TBL] [Abstract][Full Text] [Related]
9.
Eduardo Sanabria-Chanaga E; Betancourt-Conde I; Hernández-Campos A; Téllez-Valencia A; Castillo R
J Biomol Struct Dyn; 2019 Oct; 37(16):4301-4311. PubMed ID: 30477412
[TBL] [Abstract][Full Text] [Related]
10. Identification of Multi-kinase Allosteric Inhibitors of Oncogenic Targets EGFR1, PI3K, and BRAF Kinase.
Kakarala KK; Jamil K
Curr Comput Aided Drug Des; 2022; 18(7):506-518. PubMed ID: 36321226
[TBL] [Abstract][Full Text] [Related]
11. Drug repurposing for chronic myeloid leukemia: in silico and in vitro investigation of DrugBank database for allosteric Bcr-Abl inhibitors.
Singh VK; Chang HH; Kuo CC; Shiao HY; Hsieh HP; Coumar MS
J Biomol Struct Dyn; 2017 Jun; 35(8):1833-1848. PubMed ID: 27353341
[TBL] [Abstract][Full Text] [Related]
12. Identification of Dual-Target Inhibitors for Epidermal Growth Factor Receptor and AKT: Virtual Screening Based on Structure and Molecular Dynamics Study.
Yang H; Zhang Z; Liu Q; Yu J; Liu C; Lu W
Molecules; 2023 Nov; 28(22):. PubMed ID: 38005329
[TBL] [Abstract][Full Text] [Related]
13. In silico screening of neurokinin receptor antagonists as a therapeutic strategy for neuroinflammation in Alzheimer's disease.
Satarker S; Maity S; Mudgal J; Nampoothiri M
Mol Divers; 2022 Feb; 26(1):443-466. PubMed ID: 34331670
[TBL] [Abstract][Full Text] [Related]
14. Computational investigation of imidazopyridine analogs as protein kinase B (Akt1) allosteric inhibitors by using 3D-QSAR, molecular docking and molecular dynamics simulations.
Gu X; Wang Y; Wang M; Wang J; Li N
J Biomol Struct Dyn; 2021 Jan; 39(1):63-78. PubMed ID: 31838955
[TBL] [Abstract][Full Text] [Related]
15. Combined Treatment with Triptolide and Tyrosine Kinase Inhibitors Synergistically Enhances Apoptosis in Non-small Cell Lung Cancer H1975 Cells but Not H1299 Cells through EGFR/Akt Pathway.
Tong X; Jiang P; Li Y; Guo L; Zhang HM; Zhang BK; Yan M
Chem Pharm Bull (Tokyo); 2019 Aug; 67(8):864-871. PubMed ID: 31142691
[TBL] [Abstract][Full Text] [Related]
16. Structural modification of resveratrol analogue exhibits anticancer activity against lung cancer stem cells via suppression of Akt signaling pathway.
Thongsom S; Racha S; Petsri K; Ei ZZ; Visuttijai K; Moriue S; Yokoya M; Chanvorachote P
BMC Complement Med Ther; 2023 Jun; 23(1):183. PubMed ID: 37270520
[TBL] [Abstract][Full Text] [Related]
17. Computational repurposing approach for targeting the critical spike mutations in B.1.617.2 (delta), AY.1 (delta plus) and C.37 (lambda) SARS-CoV-2 variants using exhaustive structure-based virtual screening, molecular dynamic simulations and MM-PBSA methods.
Ebrahimi M; Karami L; Alijanianzadeh M
Comput Biol Med; 2022 Aug; 147():105709. PubMed ID: 35728285
[TBL] [Abstract][Full Text] [Related]
18. CHK1 kinase inhibition: identification of allosteric hits using MD simulations, pharmacophore modeling, docking and MM-PBSA calculations.
Al-Shar'i N; Musleh SS
Mol Divers; 2022 Apr; 26(2):903-921. PubMed ID: 33686514
[TBL] [Abstract][Full Text] [Related]
19.
Patel HM; Ahmad I; Pawara R; Shaikh M; Surana S
J Biomol Struct Dyn; 2021 Mar; 39(4):1491-1505. PubMed ID: 32102624
[TBL] [Abstract][Full Text] [Related]
20. Machine learning driven drug repurposing strategy for identification of potential RET inhibitors against non-small cell lung cancer.
Ramesh P; Karuppasamy R; Veerappapillai S
Med Oncol; 2022 Dec; 40(1):56. PubMed ID: 36542155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
